Novel β-lactam antibiotics and inhibitor combinations

Bibliography

• Goffin C, Ghuysen JM. Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol Mol Biol Rev 1998;62:1079-93
   PubMed Web of Science ®Google Scholar
• Lim D, Strynadka NCJ. Structural basis for the beta-lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 2002;9:870-6
   PubMedGoogle Scholar
• Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-73
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Chakrabarti P. Altered permeability and beta-lactam resistance in a mutant of Mycobacterium smegmatis. Antimicrob Agents Chemother 1997;41:1721-4
   PubMed Web of Science ®Google Scholar
• Livermore DM. Beta-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998;41:25-41
   PubMedGoogle Scholar
• Ambler RP. The structure of b-lactamases. Philos Trans R Soc Lond B Biol Sci 1980;289:321-31
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33
   PubMed Web of Science ®Google Scholar
• Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84
   PubMed Web of Science ®Google Scholar
• Thomson KS, Smith Moland E. Version 2000: the new beta-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect 2000;2:1225-35
   PubMed Web of Science ®Google Scholar
• Nouda H, Harabe ET, Sumita Y, et al. Beta-lactamase stability and inhibitory activity of meropenem combined with a potent antibacterial activity. Chemotherapy 1992;38:218-24
   PubMed Web of Science ®Google Scholar
• Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002;46:1-11
   PubMed Web of Science ®Google Scholar
• Yang K, Guglielmo JB. Diagnosis and treatment of extended-spectrum and AmpC β-lactamase-producing organisms. Ann Pharmacother 2007;41:1427-35
   PubMed Web of Science ®Google Scholar
• Paterson DL, Hujer KM, Hujer AM, et al. Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother 2003;47:3554-60
   PubMed Web of Science ®Google Scholar
• Kuzin AP, Nukaga M, Nukaga Y, et al. Structure of the SHV-1 β-lactamase. Biochemistry 1999;38:5720-7
   PubMed Web of Science ®Google Scholar
• Danel F, Hall LM, Duke B, Gur D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43:1362-6
   PubMed Web of Science ®Google Scholar
• Cuzon G, Naas T, Demachy MC, Nordmann P. Plasmid-mediated carbapenem-hydrolyzing {beta}-lactamase KPC-2 in Klebsiella pneumoniae from Greece. Antimicrob Agents Chemother 2008;52(2):796-7
   PubMed Web of Science ®Google Scholar
• Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005;352:380-91
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007;20:440-58
   PubMed Web of Science ®Google Scholar
• Miller LA, Ratnam K, Payne DJ. Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001;1:451-8
   PubMedGoogle Scholar
• Yang Y, Janota K, Tabei K, et al. Mechanism of inhibition of the class A β-lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry. J Biol Chem 2000;275:2674-82
   Google Scholar
• Massova I, Mobashery S. Molecular bases for interactions between beta-lactam antibiotics and beta-lactamases. Acc Chem Res 1997;30:162-8
   Web of Science ®Google Scholar
• Massova I, Mobashery S. Structural and mechanistic aspects of evolution of beta-lactamases and penicillin-binding proteins. Curr Pharm Des 1999;5:929-37
   PubMed Web of Science ®Google Scholar
• Venkatesan AM, Agarwal A, Abe T, et al. Novel imidazole substituted 6-methylidene-penems as broad-spectrum β-lactamase inhibitors. Bioorg Med Chem 2004;12:5807-17
   PubMed Web of Science ®Google Scholar
• Weiss WJ, Petersen PJ, Murphy TM, et al. In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors. Antimicrob Agents Chemother 2004;48:4589-96
   PubMed Web of Science ®Google Scholar
• Richter HGF, Angehrn P, Hubschwerlen C, et al. Design, synthesis, and evaluation of 2β-alkenyl penam sulfone acids as inhibitors of blactamases. J Med Chem 1996;39:3712-22
   PubMed Web of Science ®Google Scholar
• Tzouvelekis L, Gazouli M, Prinarakis EE, et al. Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against β-lactamases that belong to groups 1, 2b, and 2be. Antimicrob Agents Chemother 1997;41:475-7
   PubMed Web of Science ®Google Scholar
• Di Giacomo B, Tarzia G, Bedini A, et al. Synthesis of new C-6 alkyliden penicillin derivatives as beta-lactamase inhibitors. Farmaco 2002;57:273-83
   PubMedGoogle Scholar
• Buynak JD, Gadhachanda VR, Vogeti L, et al. Synthesis and evaluation of 3-(carboxymethylidene)- and 3-(carboxymethyl) penicillinates as inhibitors of beta-lactamase. J Org Chem 2005;70:4510-3
   PubMed Web of Science ®Google Scholar
• Kaur K, Adediran SA, Lan MJ, Pratt RF. Inhibition of beta-lactamases by monocyclic acyl phosph(on)ates. Biochemistry 2003;18:1529-36
   Google Scholar
• Miller LA, Ratnam K, Payne DJ. Beta-lactamase inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001;1:451-8
   PubMedGoogle Scholar
• Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51
   PubMed Web of Science ®Google Scholar
• Jones RN. Important and emerging beta-lactamase mediated resistances in hospital-based pathogens: the AmpC enzymes. Diagn Microbiol Infect Dis 1998;31:461-6
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Miossec C, et al. NXL104/cephalosporin combinations vs. Enterobacteriaceae with CTX-M ESBLs. In: Program and Abstracts: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 17 – 20 2007. Abstract F1-319
   Google Scholar
• Miossec C, Poirel L, Livermore D, et al. In vitro activity of the new β-lactamase inhibitor NXL 104: restoration of ceftazidime (CAZ) efficacy against carbapenem-resistant Enterobacteriaceae strains. In: Program and Abstracts: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 17 – 20 2007. Abstract F1-318
   Google Scholar
• Cherry PC, Newall CE, Watson NS. Preparation of the 7-oxo-4-oxa-1-azabicyclo[3.2.0]hept-2-ene system and the reversible cleavage of its oxazoline ring. J Chem Soc Chem Commun 1978;11:469-70
   Google Scholar
• Pfaendler HR, Weisner F, Metzger K. Synthesis and antibacterial activity of (1_R, 5R, 6R)-2-tert-butyl-6-(1_-hydroxyethyl)oxapenem-3-carboxylic acid. Bioorg Med Chem Lett 1993;3:2211-8
   Web of Science ®Google Scholar
• Jamieson CE, Lambert PA, Simpson IN. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms. Antimicrob Agents Chemother 2003;47:2615-8
   PubMed Web of Science ®Google Scholar
• Hamilton-Miller JM. Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem. Pharmacotherapy 2003;23:1497-507
   PubMed Web of Science ®Google Scholar
• Felmingham D, Robbins MJ, Mathias IL, et al. In vitro activity of faropenem, an oral penem. Abstracts of the Interscience Conference. Antimicrob Agents Chemother 2000;40:17-20
   Google Scholar
• Dalhoff A, Janjic N, Echols R. Redefining penems. Biochem Pharmacol 2006;30:1085-95
   Google Scholar
• Moellering RC. Problems with antimicrobial resistance in gram-positive cocci. Clin Infect Dis 1998;26:1177-8
   PubMed Web of Science ®Google Scholar
• Woodford N. Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Clin Microbiol Infect 2005;11:2-21
   PubMed Web of Science ®Google Scholar
• Chambers HF, Hartman BJ, Tomasz A. Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. J Clin Invest 1985;76:325-31
   PubMed Web of Science ®Google Scholar
• Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000;44:1549-55
   PubMed Web of Science ®Google Scholar
• Ito T, Kuwahara K, Hiramatsu K. Staphylococcal cassette chromosome mec (SCC mec) analysis of MRSA. Methods Mol Biol 2007;391:87-102
   PubMedGoogle Scholar
• Ito T, Katayama Y, Asada K, et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:1323-36
   PubMed Web of Science ®Google Scholar
• Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002;46:1147-52
   PubMed Web of Science ®Google Scholar
• Chambers HF. Ceftobiprole: in vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect 2006;12:17-22
   PubMed Web of Science ®Google Scholar
• Page MG. Anti-MRSA beta-lactams in development. Curr Opin Pharmacol 2006;6:480-5
   PubMed Web of Science ®Google Scholar
• Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001;45:825-36
   PubMed Web of Science ®Google Scholar
• Lin G, Appelbaum PC. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Diagn Microbiol Infect Dis 2008;60(2):233-5
   PubMed Web of Science ®Google Scholar
• Queenan AM, Shang W, Kania M, et al. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother 2007;51:3089-95
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Decorby M, Laing N, et al. Activity of ceftobiprole against pathogens isolated from Canadian intensive care units: results of the Canadian National Intensive Care Unit (CAN-ICU) Study. In: Program and Abstracts: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17 – 20 2007. Abstract C2-867
   Google Scholar
• Jones ME. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007;13:17-24
   PubMed Web of Science ®Google Scholar
• Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005;49:4210-9
   PubMed Web of Science ®Google Scholar
• Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 2007;58:363-5
   PubMed Web of Science ®Google Scholar
• Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007;13(Suppl 2):25-9
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Amsler K, et al. Treatment of complicated skin and skin structure infections caused by Gram-positive bacteria with ceftobiprole: results of a double-blind, randomized trial. Antimicrob Agents Chemother 2008;52:37-44
   PubMed Web of Science ®Google Scholar
• Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 2007;60:594-8
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004;7:2576-80
   Google Scholar
• Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49:3501-12
   PubMed Web of Science ®Google Scholar
• Iizawa Y, Nagai J, Ishikawa T, et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004;10:146-56
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007;51:3397-400
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60:300-11
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-16
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67:1027-52
   PubMed Web of Science ®Google Scholar
• Livermore DM, Neil W. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000;3:489-95
   PubMed Web of Science ®Google Scholar
• Rice LB, Bonomo RA. Beta-lactamases: which ones are clinically important? Drug Resist Updates 2000;3:178-89
   PubMed Web of Science ®Google Scholar
• Rasmussen BA, Bush K. Carbapenem-hydrolyzing blactamases. Antimicrob Agents Chemother 1997;41:223-32
   PubMed Web of Science ®Google Scholar
• DiNinno F, Beattie TR, Christensen BG. Aldol condensations of regiospecific penicillanate and cephalosporanate enolates. Hydroxyethylation at C-6 and C-7. J Org Chem 1977;42:2960-5
   PubMed Web of Science ®Google Scholar
• Golemi D, Maveyraud L, Ishiwata A, et al. 6-(hydroxyalkyl)penicillanates as probes for mechanisms of β-lactamases. J Antibiot 2000;53:1022-7
   PubMed Web of Science ®Google Scholar
• Buynak JD, Chen H, Vogeti L, et al. Penicillin-derived inhibitors that simultaneously target both metallo- and serine-blactamases. Bioorg Med Chem Lett 2004;14:1299-304
   PubMed Web of Science ®Google Scholar
• Mori M, Hikida M, Nishihara T, et al. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J Antimicrob Chemother 1996;37:1034-6
   PubMed Web of Science ®Google Scholar
• Ge Y, Wikler MA, Sahm DF, et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004;48:1384-96
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004;48:3136-40
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Hammel JP, Cirincione BB, et al. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005;49:3944-7
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ, et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004;54:144-54
   PubMed Web of Science ®Google Scholar
• Watanabe A, Takahaski H, Kikuchi T, et al. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy 2000;46:184-7
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004;48:1313-9
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005;11:974-84
   PubMed Web of Science ®Google Scholar
• Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of doripenem vs imipenem for ventilator associated pneumonia. In: Program and Abstracts: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17 – 20 2007. Abstract L-486
   Google Scholar
• Solomkin J, Umeh O, Jiang J, et al. Doripenem vs meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections. In: Program and Abstracts: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17 – 20 2007. Abstract L-487
   Google Scholar
• Rea-Neto A, Niederman M, Prokicimer P, et al. Efficacy and safety of intravenous doripenem vs piperacillin/tazobactam in nosocomial pneumonia. In: Program and Abstracts: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17 – 20, 2007. Abstract L-731
   Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacteria isolated from infected diabetic foot wounds. Antimicrob Agents Chemother 2008;52(2):761-6
   PubMed Web of Science ®Google Scholar
• Maruyama T, Yamamoto Y, Kano Y, et al. CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity. Bioorg Med Chem 2007;15:6379-87
   PubMed Web of Science ®Google Scholar